Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: Potentials and pitfalls

Clinical and Translational Oncology

Volumn 14, Issue 1, 2012, Pages 15-20

  Díaz Padilla, Iván ^a,b   Abdul Razak, Albiruni Ryan ^b   Minig, Lucas ^a   Bernardini, Marcus Q ^b   Del Campo, Josep María ^c  

^a Hospital Universitario Madrid Norte Sanchinarro   (Spain)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

CA 125; Cytoreduction; Nadir; Ovarian cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DRUG EFFICACY; DRUG MONITORING; HUMAN; MEDICAL DECISION MAKING; OVARY CARCINOMA; PREDICTIVE VALUE; PROGNOSIS; RELIABILITY; REVIEW;

ANIMALS; CA-125 ANTIGEN; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84860760717     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0756-8     Document Type: Review

References (46)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248-1259 (Pubitemid 34177431)
3. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519-2529
4. Bast RC Jr, Badgwell D, Lu Z et al (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15[Suppl 3]:274-281 (Pubitemid 43096594)
5. Duffy MJ, Bonfrer JM, Kulpa J et al (2005) CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 15:679-691 (Pubitemid 41783071)
6. Gadducci A, Cosio S, Fanucchi A et al (2004) The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol 93:131-136 (Pubitemid 38429561)
7. Riedinger JM, Wafflart J, Ricolleau G et al (2006) CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol 17:1234-1238 (Pubitemid 44288214)
8. Rocconi RP, Matthews KS, Kemper MK et al (2009) The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol 114:242-245
9. Rustin GJ, van der Burg ME, Griffin CL et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376:1155-1163
10. Bast RC Jr (2010) CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate bio-marker for a difficult disease. Cancer 116:2850-2853
11. Goonewardene TI, Hall MR, Rustin GJ (2007) Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 8:813-821 (Pubitemid 47308670)
12. Vorgias G, Iavazzo C, Savvopoulos P et al (2009) Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gy-necol Oncol 112:11-15
13. Chi DS, Venkatraman ES, Masson V, Hoskins WJ (2000) The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77:227-231 (Pubitemid 30317140)
14. Gemer O, Segal S, Kopmar A (2001) Preoperative CA-125 level as a predictor of non optimal cy-toreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand 80:583-585 (Pubitemid 32521301)
15. Cooper BC, Sood AK, Davis CS et al (2002) Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 100:59-64 (Pubitemid 34722843)
16. Saygili U, Guclu S, Uslu T et al (2002) Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 86:57-61 (Pubitemid 34757052)
17. Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R (2003) CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 13:120-124 (Pubitemid 37055464)
18. Obeidat B, Latimer J, Crawford R (2004) Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Invest 57:153-156 (Pubitemid 38410702)
19. Barlow TS, Przybylski M, Schilder JM et al (2006) The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 16:496-500
20. Arits AH, Stoot JE, Botterweck AA et al (2008) Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer 18:621-628 (Pubitemid 352020153)
21. Gemer O, Lurian M, Gdalevich M et al (2005) A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 31:1006-1010 (Pubitemid 41671115)
22. Alcazar JL, Miranda D, Unanue A et al (2004) CA-125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma. Int J Gynaecol Obstet 84:173-174 (Pubitemid 38210015)
23. Brockbank EC, Ind TE, Barton DP et al (2004) Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 14:42-50 (Pubitemid 38280622)
24. Mury D, Woelber L, Jung S et al (2011) Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer. J Cancer Res Clin Oncol 137:1131-1137
25. Kang S, Kim TJ, Nam BH et al (2010) Preopera-tive serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol 101:13-17
26. Chi DS, Zivanovic O, Palayekar MJ et al (2009) A contemporary analysis of the ability of preopera-tive serum CA-125 to predict primary cytoreduc-tive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 112:6-10
27. Kang S, Kim TJ, Seo SS et al (2011) Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Gynecol Oncol 120:18-22
28. Talbot RW, Jacobsen DJ, Nagorney DM et al (1989) Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet 168:407-412 (Pubitemid 19147691)
29. van der Zee AG, Duk JM, Aalders JG et al (1990) The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. Br J Obstet Gynaecol 97:934-938 (Pubitemid 20340627)
30. Yoo SC, Yoon JH, Lyu MO et al (2008) Sig-nificance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer. J Gynecol Oncol 19:169-172
31. Zivanovic O, Sima CS, Iasonos A et al (2009) Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol 115:209-214
32. Rustin GJ, Vergote I, Eisenhauer E et al (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21:419-423
33. Crawford SM, Peace J (2005) Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 16:47-50 (Pubitemid 40124477)
34. Markman M, Liu PY, Rothenberg ML et al (2006) Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 24:1454-1458 (Pubitemid 46622013)
35. Juretzka MM, Barakat RR, Chi DS et al (2007) CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 104:176-180 (Pubitemid 46054121)
36. Prat A, Parera M, Peralta S et al (2008) Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol 19:327-331 (Pubitemid 351201715)
37. Kang S, Seo SS, Park SY (2009) Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer. J Surg Oncol 100:244-247
38. van Altena AM, Kolwijck E, Spanjer MJ et al (2011) CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. Gynecol Oncol 119:265-269
39. Bast RC Jr, Klug TL, St John E et al (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887 (Pubitemid 13014028)
40. Riedinger JM, Eche N, Basuyau JP et al (2008) Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. Gynecol Oncol 109:194-198
41. Axtell AE, Lee MH, Bristow RE et al (2007) Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 25:384-389 (Pubitemid 350002986)
42. Mercado C, Zingmond D, Karlan BY et al (2010) Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol 117:18-22
43. Harter P, Hilpert F, Mahner S et al (2009) Prognostic factors for complete debulking in first- and second-line ovarian cancer. Int J Gynecol Cancer 19[Suppl 2]:S14-17
44. Zorn KK, Tian C, McGuire WP et al (2009) The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 115: 1028-1035
45. Altundag K, Altundag O, Morandi P, Gunduz M (2005) CA125 nadir values as a prognostic factor in epithelial ovarian cancer. J Clin Oncol 23: 2435-2436; author reply 6 (Pubitemid 46218745)
46. Tuxen MK, Soletormos G, Petersen PH, Domber-nowsky P (2001) Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue poly-peptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer. Clin Chem Lab Med 39:531-538 (Pubitemid 32685406)